Navigation Links
Cutanea Announces Promising Phase II Results in Rosacea with Omiganan
Date:10/17/2007

orward to a more precise estimation of the effectiveness of the drug in the larger Phase III program."

The objective of this exploratory Phase II study was to find the optimal dose and regimen of Omiganan for further study as a treatment for rosacea. The trial enrolled 240 patients with papulopustular rosacea and Investigator Global Assessment (IGA) scores of grade 3 or 4 (moderate to severe disease). Patients were randomized into one of five treatment groups in a 2:2:2:1:1 ratio: Omiganan 1% QD, Omiganan 2.5% QD, Omiganan 2.5% twice-daily (BID), Vehicle QD, or Vehicle BID. During the total nine-week treatment period, safety and efficacy assessments were performed at weeks one, three, six, and nine.

The primary efficacy endpoint was mean percent reduction in the number of inflammatory lesions from Baseline to Week 9. Patients receiving once-daily Omiganan 2.5% showed a mean 31% reduction in the number of inflammatory facial lesions compared to a 14% reduction in patients receiving once-daily vehicle. And, among rosacea patients with 18 or more lesions at Baseline, the mean reduction for once-daily Omiganan 2.5% was 40%, compared to an 11% lesion increase in the once-daily vehicle group.

Secondary endpoints included the absolute change from Baseline in the number of inflammatory lesions at Week nine and at each interim visit, the percent change in number of inflammatory lesions at interim visits, the absolute change from Baseline in IGA score and other signs and symptoms of rosacea at Week nine and each interim visit, and Treatment Success at Week nine and each interim visit.

Although a statistically significant difference between active and vehicle was not achieved for the primary endpoint, this study demonstrated that in both the intent-to-treat and the per protocol populations, Omiganan 2.5% QD was statistically significantly better than vehicle QD at Week nine in the absolute change of inflammatory lesions (p=0.041 for intent-to-treat, and
'/>"/>

SOURCE Cutanea Life Sciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)...  Boston Scientific has released the primary endpoint ... Failure (NECTAR-HF) clinical trial, the first and only ... (VNS) for the treatment of heart failure patients.  ... Cardiology and Director of the Clinical Investigation Center ... de la Recherche Medicale presented the results at ...
(Date:8/30/2014)... 30, 2014   Royal Philips  (NYSE: PHG, AEX: ... a new ultrasound system designed to enable global hospitals ... patient volumes and cost pressures. Making its debut at ... Barcelona this week, Affiniti provides ... with fewer resources deliver high quality patient care. ...
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... The report firstly reviews the basic information of ... manufacturing technology. The report then explores global and ... their product specification, capacity, Production value, and market ...
Breaking Medicine Technology:Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5
(Date:8/30/2014)... 30, 2014 According to Bloomberg ... that requires Takeda Pharmaceutical Co. and Eli Lilly & ... claims that the drugmakers concealed information about a risk ... The case, Allen v. Takeda Pharmaceuticals North America Inc. ... District of Louisiana (Lafayette).* , According to Bloomberg, Takeda ...
(Date:8/30/2014)... Recently, Skmen.com, a well-known clothing manufacturer, has ... . Before the middle of September, all the company’s ... from 15 to 30 percent off. , As ... outfits are carefully made and come with quality guarantees. ... wearers. Skmen.com is popular for its fashionable, high quality ...
(Date:8/30/2014)... CA (PRWEB) August 30, 2014 Ticket Down ... vs. Chile exhibition match next Saturday at Levi's Stadium. ... for diehard soccer fans in the United States due to the ... in just about every major city. Many of these games ... in Brazil this past summer. , Levi’s Stadium is a brand ...
(Date:8/30/2014)... 2014 Information supplied by insurance companies ... better prices to consumers in 2014. A group of ... when using the open system for adults at ... to use this year can help the average person ... location and not from medical histories. The finder tool ...
(Date:8/30/2014)... 2014 United Theological Seminary is pleased to ... the Master of Theological Studies (MTS). , ... designed for students who wish to pursue further academic study ... to serve the Church and community. Previously, students needed to ... can attend classes from any location where there is an ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Decision to Uphold $9 Billion Actos Award 2Health News:Huge Deals On 2014 Long Casual Dresses Unveiled By Skmen.com 2Health News:Mexico vs. Chile Tickets at Levi's Stadium in Santa Clara, CA: TicketDown.com Offers Promo Code for Mexico vs. Chile Exhibition Game on September 6th 2Health News:Term Life Insurance Rates Now Found Nationally by New Insurer Finder Tool 2Health News:United Theological Seminary Announces First Fully Online Degree 2
... finds increased risk of heart failure , , MONDAY, Dec. 22 (HealthDay ... inactivity increased the risk of heart failure in a major study ... overweight men who are not obese have an increase in heart ... on the finding in the Dec. 23 issue of Circulation ...
... December 22, 2008 The Women,s Heart Health Initiative ... creation of a new fellowship dedicated to gender-specific research ... heart disease in women. The announcement will take place ... , "Women face unique challenges to successful diagnosis ...
... almost 4 times the odds, study says , , MONDAY, ... increases a pregnant woman,s likelihood of having a Caesarean ... Boston University School of Medicine and Boston Medical Center ... pregnant women and Caesarean section. Of the 253 women ...
... of suffering from overweight and obesity. This is the result ... starting school. Elisabeth Weber and her coauthors present the results ... ( Dtsch Arztbl Int 2008; 105 [51-52]: 883-9). The ... of the children, but also their mother tongue. Their parents ...
... switch ,on, in those with lupus, rheumatoid arthritis , , ... potential autoimmune disease-causing cells, but these cells stay in ... cells that attack the body cause autoimmune diseases such ... cells in healthy adults are true precursors of the ...
... the Support of Long Term Care elects healthcare software expert Eric Christ ... ... -- The National Association for the Support of Long Term Care (NASL) ... the president of Patient Placement Systems , part of the Jackson ...
Cached Medicine News:Health News:Even a Little Overweight, Inactivity Hurts the Heart 2Health News:Eric Christ of Long-Term Care Software Leader Patient Placement Systems' Elected to NASL Board of Directors 2
... The Minifold I system consists of four basic ... plenum, and metal clamping plate (see diagram). The ... for producing spots, dots, or slots (see below). ... purchased as an accessory plate in conjunction with ...
... The Minifold I system consists of four basic ... plenum, and metal clamping plate (see diagram). The ... for producing spots, dots, or slots (see below). ... purchased as an accessory plate in conjunction with ...
... Bio-Dot SF (slot format) microfiltration units provide ... nucleic acid in solution onto nitrocellulose or ... accommodated by using interchangeable templates to form ... format Bio-Dot SF apparatus. Each is available ...
... The Bio-Dot and Bio-Dot SF (slot ... for binding protein or nucleic acid in ... experimental protocols can be accommodated by using ... apparatus or 48-well slot format Bio-Dot SF ...
Medicine Products: